Latest news
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer - Business WireBusiness Wire · Wed, 05 Aug 2026 11:00:00 GMTLAMC2+ Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3/STAT3/CD44 Axis - Wiley Online LibraryWiley Online Library · Wed, 05 Aug 2026 07:00:00 GMT